a Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Pharmaceutical Sciences, Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China;
b Chongqing Engineering Research Center of Pharmaceutical Sciences, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China
Funds:
This work was supported by the National Natural Science Foundation of China (Grant Nos. 82373841 and 82003710), the Basic and Applied Basic Research Foundation of Guangdong Province (Grant No. 2024A1515011385), the Guangzhou Basic and Applied Basic Research Foundation (Grant No. 2025A04J7083), and a Grant from the Guangdong Pharmaceutical University (Grant No. 2024QZ01).
Cardiac troponin I (cTnI), a widely used biomarker for assessing cardiovascular risk, can provide a window for the evaluation of drug-induced myocardial injury. Label-free biosensors are promising candidates for detecting cell secretomes, since they do not require labor-intensive processes. In this work, a label-free electrochemical aptasensor is developed for in situ monitoring of cardiac cell secretomes in cell culture media based on target-induced strand displacement. The aptasensing system contains an aptamer-functionalized signal nanoprobe facing trimetallic metal-organic framework nanosheets and a gold nanoparticle-based detection working electrode modified with DNA nanotetrahedron-based complementary DNA for indirect target detection. The signal nanoprobes (termed CAHA) consisted of copper-based metal-organic frameworks, AuPt nanoparticles, horseradish peroxidase, and an aptamer. When the aptasensor is exposed to cardiac cell secretomes, cTnI competitively binds to the aptamer, resulting in the release of signal nanoprobes from the biorecognition interface and electrochemical signal changes. The aptasensor exhibited rapid response times, a low detection limit of 0.31 pg mL-1, and a wide linear range of 0.001-100 ng mL-1. We successfully used this aptasensor to measure cTnI concentrations among secreted cardiac markers during antitumor drug treatment. In general, aptasensors can be used to monitor a variety of cardiac biomarkers in the evaluation of cardiotoxicity.